BC Week In Review | Mar 3, 2017
Company News

Ligand, Sermonix expand 2015 deal

Ligand and Sermonix added rights in the rest of the world to a 2015 deal granting Sermonix U.S. rights to develop and commercialize oral lasofoxifene . Ligand will receive an undisclosed upfront payment and is eligible...
BC Week In Review | Feb 9, 2015
Company News

Ligand, Sermonix Pharmaceuticals deal

Ligand granted Sermonix rights to develop and commercialize oral lasofoxifene in the U.S. and additional undisclosed territories. Ligand has received an undisclosed upfront payment and is eligible to receive up to $45 million in regulatory...
BC Week In Review | Aug 11, 2014
Clinical News

Lasofoxifene: Phase I data

An investigator-blinded, placebo-controlled Phase I trial in 36 healthy male volunteers showed that single doses of 1, 3, 10, 30 and 100 mg oral lasofoxifene increased testosterone levels, with the 2 highest doses increasing testosterone...
BC Week In Review | Jul 29, 2013
Company News

Azure Biotech Inc., Ethicor Pharma, Ligand deal

Ligand granted newco Azure an exclusive, worldwide license to develop and commercialize a new formulation of Ligand's osteoporosis drug lasofoxifene for an undisclosed women's health indication. Ligand is eligible to receive $2.7 million in development...
BC Week In Review | Oct 17, 2011
Company News

Ligand, Chiva Pharmaceuticals Inc. deal

Ligand granted Chiva exclusive, worldwide rights to develop and commercialize osteoporosis drug Fablyn lasofoxifene. Ligand will receive $4 million up front and is eligible for milestones and single-digit royalties. The selective estrogen receptor modulator (SERM)...
BioCentury | Oct 17, 2011
Finance

Highlights of weekly biotech stock moves

Insmed Inc. (NASDAQ:INSM) fell $1.34 (31%) to $3.01 on Monday after FDA told the company it is maintaining a clinical hold on a planned Phase III trial of Arikace in cystic fibrosis patients with Pseudomonas...
BC Extra | Oct 11, 2011
Company News

China's Chiva in-licenses osteoporosis drug Fablyn

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) granted Chiva Pharmaceuticals Inc. (Beijing, China) exclusive, worldwide rights to develop and commercialize osteoporosis drug Fablyn lasofoxifene. Ligand will receive $4 million up front and is eligible for milestones and single-digit...
BC Week In Review | Dec 6, 2010
Clinical News

Fablyn lasofoxifene: Phase III data

Lasofoxifene is marketed in Europe as Fablyn to treat osteoporosis in postmenopausal women at increased risk of fracture. In 2009, Pfizer received a complete response letter from FDA for Fablyn for the indication (see BioCentury,...
BioCentury | Jan 11, 2010
Finance

New Products to Watch

New Products to Watch Selected drugs that received regulatory approval in 2009. Company Product Indication 2009 approval Allergan Inc. (NYSE:AGN) Ozurdex dexamethasone Macular edema U.S. Allos Therapeutics Inc. (NASDAQ:ALTH) Folotyn pralatrexate Relapsed or refractory peripheral...
BioCentury | Aug 31, 2009
Strategy

Ligand pipeline

Ligand pipeline Partner Ph I Ph II Ph III Approved/Marketed Abbott Laboratories (NYSE:ABT) • LGD-2941 - hypogonadism Bristol-Myers Squibb Co. (NYSE:BMY) • PS540446 - rheumatoid arthritis (RA), psoriasis, atherosclerosis (A) Celgene Corp. (NASDAQ:CELG) • PS873266 - inflammation (A)...
Items per page:
1 - 10 of 59